To further raise public awareness of the quality and safety of in vitro diagnostic reagents and promote the principle of “rational use of medical devices for a healthy life,” the “In Vitro Diagnostic Reagent Quality Campaign” was recently launched in Zhuhai. The event was guided by the Medical Device Supervision Department of the National Medical Products Administration, organized by the China Pharmaceutical News Information Association, and co-hosted by the Guangdong Provincial Food and Drug Administration and the Zhuhai Municipal Food and Drug Administration.
This event employs a variety of science‑communication and public‑education initiatives—such as legal‑regulatory consultations, identification of counterfeit and substandard products, displays of renowned enterprise‑branded goods, interactive public experiences, and free medical screenings at healthcare institutions—to bring together regulatory authorities, key manufacturers and operators, testing agencies, industry professionals, and the media for face‑to‑face dialogue. The aim is to gain insights into the current state of industry development and to disseminate exemplary practices and tangible results. Through in‑depth research and interviews with in‑vitro diagnostic reagent manufacturers in Zhuhai, the initiative seeks to assess the current landscape of product categories, evaluate enterprises’ quality‑and‑safety management systems, and other relevant factors. By doing so, it encourages businesses and medical institutions to strengthen their commitment to quality and compliance, advance the establishment of an integrity‑based system, elevate quality‑management standards, and steer the industry toward sustainable, healthy growth.

At present, with the rapid economic and social development of Zhuhai, the city’s medical device industry—particularly the in vitro diagnostic reagent sector—has demonstrated strong growth momentum across production, sales, R&D, and profitability. The city is home to 20 in vitro diagnostic reagent manufacturers, with an output value approaching RMB 800 million, and has seen the emergence of several well‑known industry leaders.

2015 year 6 month 11 day   Dier showcased its flagship products at the opening ceremony, absorbed and embraced the spirit of the event, presented its offerings and corporate culture to the public and the media, and promoted the responsible use of antibiotics.

12 On [date], the “Quality Across the Country for In-Vitro Diagnostic Reagents” initiative paid a visit to Dier. Leaders from the provincial and municipal food and drug administration, along with representatives from Xinhua News Agency, Southern Daily, and other media outlets, toured the company and its exhibition hall. They gained an in-depth understanding of the company’s reagent‑production processes and automated equipment, inspected the Class 100 cleanroom, and held a roundtable discussion with the company’s senior executives responsible for production and quality. During the meeting, they thoroughly reviewed the company’s development progress and expressed high praise for Dier’s quality management, brand awareness, and strategic direction.

News link from the Zhuhai Municipal Food and Drug Administration:

http://zh.gdda.gov.cn/publicfiles/business/htmlfiles/fdazh/pmid01/201506/302703.htm

Guangdong Provincial Food and Drug Administration news link:

http://www.gdfda.gov.cn/publicfiles/business/htmlfiles/jsjzz/pgeshidongtai/201506/303089.htm